BioAlliance Pharma, a company developing specialty and orphan oncology products has declared the commencement of the production of clinical batches of Livatag, a regimen to supply doxorubicin in nanoparticle form to chemoresistant cells, for its phase III clinical trial for primary liver cancer.
In the United States and Europe, Livatag was secured an orphan drug category. Livatag’s clinical batches production will be done by authorized companies dealing with injectable cytotoxic products in the form of nanoparticles. The industrial development team of BioAlliance Pharma and its partners will collaborate in the entire process to assure transmission of its expertise in the nanoparticle Transdrug technology.
The clinical trial batches production is one of the landmarks of phase III clinical trial of Livatag in primary liver cancer. It is the final development stage of the product. BioAlliance Pharma has increased the protection of its nanoparticle Transdrug technology by securing a second European patent. This leverages Livatag’s industrial property and fulfills the market uniqueness obtained through its orphan status, which in turn strengthens the worth of this important asset of the company.
Judith Greciet, who serves as Chief Executive Officer at BioAlliance Pharma, stated that based on their unique expertise in nanotechnology, the company’s industrial development team and its European collaborators are dedicated to organize the clinical batches production of Livatag.